Stocks · News reference

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

Sep 24, 2026, 5:31 PMVandana Singh

aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis, beginning in Q4 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 13, 2026, 12:04 PMBenzinga Newsdesk
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Journal Of Biological Chemistry
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic
ATYR
BenzingaSep 24, 2026, 7:40 PMBenzinga Newsdesk
aTyr Pharma shares are trading lower. The company announced it reached alignment with the FDA on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis.
ATYR
SEC EDGARSep 24, 2026, 11:47 AMSEC EDGAR
8-K filing — aTYR PHARMA INC (ATYR)
Filed: 2026-09-24 AccNo: 0001339970-26-000065 Size: 172 KB Item 8.01: Other Events
ATYR